264 related articles for article (PubMed ID: 24371224)
1. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
Menges CW; Kadariya Y; Altomare D; Talarchek J; Neumann-Domer E; Wu Y; Xiao GH; Shapiro IM; Kolev VN; Pachter JA; Klein-Szanto AJ; Testa JR
Cancer Res; 2014 Feb; 74(4):1261-1271. PubMed ID: 24371224
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
3. A mouse model recapitulating molecular features of human mesothelioma.
Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR
Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281
[TBL] [Abstract][Full Text] [Related]
4. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma.
Lecomte C; Andujar P; Renier A; Kheuang L; Abramowski V; Mellottee L; Fleury-Feith J; Zucman-Rossi J; Giovannini M; Jaurand MC
Cell Cycle; 2005 Dec; 4(12):1862-9. PubMed ID: 16319530
[TBL] [Abstract][Full Text] [Related]
5. Animal models of malignant mesothelioma.
Kane AB
Inhal Toxicol; 2006 Nov; 18(12):1001-4. PubMed ID: 16920675
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
Baser ME; Rai H; Wallace AJ; Evans DG
Fam Cancer; 2005; 4(4):321-2. PubMed ID: 16341811
[TBL] [Abstract][Full Text] [Related]
8. Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53+/- mice.
Vaslet CA; Messier NJ; Kane AB
Toxicol Sci; 2002 Aug; 68(2):331-8. PubMed ID: 12151629
[TBL] [Abstract][Full Text] [Related]
9. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
Sneddon S; Patch AM; Dick IM; Kazakoff S; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
BMC Cancer; 2017 Jun; 17(1):396. PubMed ID: 28577549
[TBL] [Abstract][Full Text] [Related]
10. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours.
Fleury-Feith J; Lecomte C; Renier A; Matrat M; Kheuang L; Abramowski V; Levy F; Janin A; Giovannini M; Jaurand MC
Oncogene; 2003 Jun; 22(24):3799-805. PubMed ID: 12802287
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
[TBL] [Abstract][Full Text] [Related]
12. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma.
Murthy SS; Testa JR
J Cell Physiol; 1999 Aug; 180(2):150-7. PubMed ID: 10395284
[TBL] [Abstract][Full Text] [Related]
13. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.
Bianchi AB; Mitsunaga SI; Cheng JQ; Klein WM; Jhanwar SC; Seizinger B; Kley N; Klein-Szanto AJ; Testa JR
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10854-8. PubMed ID: 7479897
[TBL] [Abstract][Full Text] [Related]
14. KRAS signaling in malignant pleural mesothelioma.
Marazioti A; Krontira AC; Behrend SJ; Giotopoulou GA; Ntaliarda G; Blanquart C; Bayram H; Iliopoulou M; Vreka M; Trassl L; Pepe MAA; Hackl CM; Klotz LV; Weiss SAI; Koch I; Lindner M; Hatz RA; Behr J; Wagner DE; Papadaki H; Antimisiaris SG; Jean D; Deshayes S; Grégoire M; Kayalar Ö; Mortazavi D; Dilege Ş; Tanju S; Erus S; Yavuz Ö; Bulutay P; Fırat P; Psallidas I; Spella M; Giopanou I; Lilis I; Lamort AS; Stathopoulos GT
EMBO Mol Med; 2022 Feb; 14(2):e13631. PubMed ID: 34898002
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma.
Kleymenova EV; Bianchi AA; Kley N; Pylev LN; Walker CL
Mol Carcinog; 1997 Jan; 18(1):54-60. PubMed ID: 9022813
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis of malignant pleural mesothelioma.
Jaurand MC; Fleury-Feith J
Respirology; 2005 Jan; 10(1):2-8. PubMed ID: 15691231
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis.
Guled M; Lahti L; Lindholm PM; Salmenkivi K; Bagwan I; Nicholson AG; Knuutila S
Genes Chromosomes Cancer; 2009 Jul; 48(7):615-23. PubMed ID: 19396864
[TBL] [Abstract][Full Text] [Related]
19. Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.
Ou WB; Lu M; Eilers G; Li H; Ding J; Meng X; Wu Y; He Q; Sheng Q; Zhou HM; Fletcher JA
Br J Cancer; 2016 Nov; 115(10):1253-1263. PubMed ID: 27736841
[TBL] [Abstract][Full Text] [Related]
20. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
[Next] [New Search]
